Plunging global equity prices and frozen global credit markets are leading Europe into the start of its worst economic recession in the postwar period.

Durably improving health is really, really hard. I've discussed this in the context of drug discovery, which must contend with the ever-more-apparent reality that biology is incredibly complex, and science remarkably fragile. Here, I'd like to focus on another challenge: measuring and improving the quality of patient care.

Ernst R. Berndt and Anjli C. Warner discuss their new book, U.S. Markets for Vaccines: Characteristics, Case Studies, and Controversies.

Scott Gottlieb reviews Eric Topol's book on how medical innovation will coalesce to change clinical practice and what the coming changes mean for today's policy debates.

It's the first rule of Canadian economics: when the U.S. catches cold, Canada gets pneumonia. What if the rule no longer applies?

When markets are irrational, it's impossible to say what might set them off, and fear of disaster becomes a powerful excuse for policy makers to do whatever they choose.

A speculative study about the relationship between the measles, mumps, and rubella vaccine and autism in the prestigious British medical journal The Lancet was retracted today for having numerous flaws and insufficient data within it.

The only way to stay ahead of bacterial evolution is to escalate the arms race.